Orion Oyj

Board/Management Information • Mar 23, 2022

Disclosure 405998

Orion - Other information disclosed according to the rules of the Exchange

Orion Corporation: Organising meeting of the Board of Directors

ORION CORPORATION

STOCK EXCHANGE RELEASE / OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE

23 MARCH 2022 at 18.20 EET

Orion Corporation: Organising meeting of the Board of Directors

In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Hilpi Rautelin as Vice Chairman.

The compositions of the Board committees were decided to be as follows:

Personnel and Remuneration Committee:

Mikael Silvennoinen, Chairman

Maziar Mike Doustdar

Veli-Matti Mattila

Hilpi Rautelin

Audit Committee:

Ari Lehtoranta, Chairman

Kari Jussi Aho

Eija Ronkainen

Karen Lykke Sørensen

R&D Committee:

Hilpi Rautelin, Chairman

Kari Jussi Aho

Veli-Matti Mattila

Eija Ronkainen

Karen Lykke Sørensen

The Company also has a Nomination Committee, the election of which was announced in a Stock Exchange Release on 27 April 2021.

All members of the Board of Directors have been assessed to be independent of the company and its significant shareholders.

Orion Corporation

Timo Lappalainen President and CEO		Olli Huotari SVP, Corporate Functions

Contact person:

Olli Huotari, Senior Vice President, Corporate Functions

Phone +358 50 966 3054

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.